Protective effect and mechanism of ligustrazine combined with astragaloside Ⅳ on angiogenesis of human umbilical vein endothelial cells

Yu-mei LI,Xin-xin YANG,Xu HAN,Cong-cong XIE,Guang-xue HAN,Da-fang ZHANG,Chu-ying WANG
DOI: https://doi.org/10.7501/j.issn.0253-2670.2017.04.018
2017-01-01
Abstract:Objective To study the protective effect and mechanism of ligustrazine combined with astragaloside Ⅳ on hypoxia injury of human umbilical vein endothelial cells (HUVECs).Methods The model of hypoxia injury was established,and the cells for pharmacodynamics study were divided into five groups:control group,model group,ligustrazine group (80 μg/mL),astragaloside Ⅳ group (40 μg/mL),and compatibility of astragaloside Ⅳ and ligustrazine group.The effects of ligustrazine,astragaloside Ⅳ,and their compatibility on cell proliferation in each group after hypoxia injury were detected by MTT assay.Immunohistochemical method was used to observe the expression of proteins VEGF and Ang-Ⅱ in HUVECs with hypoxia injury,and Western blotting was used to observe the expression of proteins VEGF and Ang-Ⅱ.RT-PCR was used to observe the mRNA expression of VEGF and Ang-Ⅱ.Results Compared with those in the model group,cell viability of ligustrazine group,astragaloside Ⅳ group,and compatibility group significantly increased,and the best group was ligustrazine (80 μg/mL) + astragaloside Ⅳ (40 μg/mL) group.Ligustrazine (80 μg/mL) + astragaloside Ⅳ (40 μg/mL) group could up-regulate the protein expression levels of VEGF and Ang-Ⅱ and the levels of VEGF and Ang-Ⅱ mRNA.Conclusion Ligustrazine combined with astragaloside Ⅳ may be targeted by increasing angiogenesis factor,and the expression of VEGF and Ang-Ⅱ plays the role of promoting angiogenesis.
What problem does this paper attempt to address?